On the latest episode of #TheCancerSignal podcast, learn how cancer screening was impacted by the COVID-19 pandemic and what that meant for early cancer detection: bit.ly/40YYW3F

We’re initiating a real-world study to evaluate the clinical impact of #MCED screening among Medicare beneficiaries.

Learn more here: bit.ly/47IVxrB

Please see enclosed video providing a study overview: bit.ly/47FLRhB

We are proud to announce that GRAIL has received ISO 13485 Certification, which indicates that GRAIL has implemented robust policies and procedures for the development and manufacture of regulated medical products. bit.ly/3R1ADyB

We attended this year’s #ISPOREurope to present two posters on real-world implications of multi-cancer early detection ( #MCED ). Explore the results: bit.ly/3ufa1Bd

At GRAIL, we are guided by our commitment to changing the world. We are honored to be recognized as a top biopharma company on @BioSpace's 2024 Best Places to Work list. Learn more: bit.ly/3TOYVtU

Though Cindy had no symptoms, her husband, Carlos, urged her to take a multi-cancer early detection ( #MCED ) test. They were shocked when she received a “cancer signal detected” result.

Hear their story: bit.ly/44RHQVD

The PATHFINDER study investigated the impact multi-cancer early detection testing can have when added to recommended cancer screenings.

🎙️On this episode of #TheCancerSignal podcast we discuss the findings with principal investigator Dr. Chuck McDonnell: bit.ly/3SlxuuE

Did anyone catch Wordle yesterday? 😎

Wordle 863 1/6

🟩🟩🟩🟩🟩

Jeff Venstrom, GRAIL's chief medical officer, participated in the panel 'Challenges and Opportunities of Multi-Cancer Early Detection Tests' at the Precision Oncology & Diagnostics meeting in Chicago to discuss the advancement of MCEDs to reduce cancer burden.

Get ready, because year 2 of The Cancer SIGNAL Podcast is just around the corner!

🎙️ Stay tuned for more captivating discussions on multi-cancer early detection: bit.ly/3Lx4g6t

We’re proud to share that we received a Presidential Poster Award for two of our abstracts at this year’s #ACG2023 . The analyses reflect our team’s relentless pursuit to redefine #cancer screening. Learn more about our innovative technology: grail.com

Our team at #ACG2023 is sharing two abstracts that demonstrate the potential of our #MCED technology to detect cancers in individuals without suspicion of #cancer and to differentiate cancer detection in those newly diagnosed. Learn about our latest work: grail.com

Our second annual DEI Week featured ten sessions, in person and virtual, for employees to learn about equity in healthcare, allyship, DEI in business and more.

Thanks to all involved in making this week an engaging and thought-provoking opportunity to learn and connect.

Have you heard our podcast, The Cancer SIGNAL? We want to hear your thoughts!

💬 Fill out this quick survey to share your feedback for future episodes on multi-cancer early detection: bit.ly/3PV8bfZ

Today we announced a collaboration with @HCAHealthcare and Sarah Cannon Docs to offer multi-cancer early detection paired with multidisciplinary care coordination to eligible individuals.

Read more: bit.ly/3FjImBx

It's been a year of discovery on The Cancer SIGNAL podcast.

From understanding genomics to applications of AI, we’ve explored the science of #cancer screening and early detection. Thanks for tuning in and learning with us!

🎙Subscribe here: bit.ly/3Lx4g6t

Megan Hall, GRAIL's VP of Corporate Affairs, represented GRAIL in a #HLTH2023 panel discussion about cancer screening and how multi-cancer early detection testing can be added to screen for more cancers.

Learn about how #MCED works: bit.ly/45wf8ux

Gear up for a game-changing conversations at our upcoming #EDxConf23 ! Check out our platinum sponsor GRAIL’s stand to explore exciting opportunities in early #CancerScreening 👇

We're excited to share our new partnership with Accarent Health, a leader in value-based care for oncology. Learn more below.

.The Lancet published detailed outcomes from GRAIL’s PATHFINDER study. The results show how adding an MCED test with CSO prediction enabled targeted diagnostic evaluations, with most participants achieving diagnostic resolution in less than 3 months. bit.ly/3LQpX2H